Jinkai Shengke: Report for the third quarter of 2024

SZSIOct 23 12:00 ET · Announcements

Genecast Biotechnology (301509.SZ): The company's products do not involve starch or other fillers and excipients.

Golden Triumph October 23rd | Jin Kaiseng Science (301509.SZ) stated on the investor interaction platform that the company provides small molecule CDMO services, and the company's products do not involve starch and other fillers and excipients.

Gelonghui FinanceOct 23 05:12 ET

Jinkaisen Life Sciences (301509.SZ): The net income in the third quarter was 7.1988 million yuan, a year-on-year decrease of 79.02%.

GeLongHui October 23rd | Jinkaiseng Science and Technology (301509.SZ) announced its third quarter report for 2024, with revenue of 0.125 billion yuan for the reporting period, a decrease of 18.72% year-on-year; net income attributable to shareholders of the listed company was 7.1988 million yuan, a decrease of 79.02% year-on-year; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.4557 million yuan, a decrease of 98.66% year-on-year; basic earnings per share were 0.06 yuan.

Gelonghui FinanceOct 23 04:12 ET

Calculating The Fair Value Of Kingchem (Liaoning) Life Science Co., Ltd. (SZSE:301509)

Simply Wall StSep 30 03:42 ET

Jinkai Life Sciences (301509.SZ): focusing on developing European and Asia-Pacific customer base.

On September 11, Gelonghui reported that Jinkaiseng Science (301509.SZ) stated at an investor relations event that the company has been actively adjusting and has taken various measures, including: 1. Strengthening the BD team, fully leveraging the international BD team and customer resource advantages, focusing on developing customers in Europe and the Asia-Pacific region, actively expanding business increment on the basis of striving for existing customer project orders; 2. Fully leveraging the strategic support of the US GMP production base and R&D center, while hedging risks, quickly generating performance contributions from the base and introducing more projects; 3. Fully leveraging the pharmaceutical CDMO field

Gelonghui FinanceSep 11 03:02 ET

Kingchem: Half-year report for the year 2024.

SZSIAug 26 12:00 ET · Announcements